Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Guidance Sheds Light On Human Factor Studies For Combo Products

This article was originally published in The Gray Sheet

Executive Summary

Questions from companies and FDA reviewers about human factor design and data requirements for combination products continue to grow. In response, the agency has issued a draft guidance.


Related Content

ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
FDA Turns Down Sensor-Embedded Tablet For Monitoring Medication Adherence
In Case You Missed It: Top 10 Gray Sheet Stories In February
Podcast + Q&A: Combo Product Human Factors Guidance Follows Multi-Year Coalition Effort
FDA Details When Human Factors Testing Is A Must
2016 Will Be A Big Year For Combo Product Reform, FDA Says
Human Factors Questions Drive Rise In FDA Inter-Center Consults